drugset / Trial / NCT00126256

Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer

NCT00126256 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

The standard treatment of metastatic colorectal cancer is based on systemic chemotherapy. Several effective drugs are currently available and can be administered either sequentially or in combination. Most patients receive 2 or 3 lines of chemotherapy. The aim of this randomized trial is to evaluate the potential benefit of a bitherapy with 5-fluorouracil (5-FU) and oxaliplatin as first line chemotherapy compared with a sequential chemotherapy with 5-FU alone as first line chemotherapy followed by the combination of 5-FU with oxaliplatin in case of progressive disease, in terms of progression-free survival and overall survival in patients with advanced colorectal cancer.

Timeline

Start
2002-02
Primary completion
2006-02
Completion
2006-02

Outcome

Missed primary endpoint

paper hazard ratio 0·95, 95% CI 0·77-1·16; p=0·61 PMID 21903473 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule 180 mg/m2 —
Subject Leucovorin Small molecule 400 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 100 mg/m2 Intravenous
Subject fluorouracil Small molecule 250 mg/m2 Intravenous
Subject fluorouracil Small molecule 400 mg/m2 Intravenous
Subject fluorouracil Small molecule 2400 mg/m2 Intravenous